Search Results Search Sort by RelevanceMost Recent In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534. Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520. History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580. Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527. Pagination First page « First Previous page ‹ Previous … Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44 Current page 45
In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534.
Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520.
History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580.
Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527.